Toon Laeremans

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

The International Federation of Pharmaceutical Manufacturers and Traders is a global organization that promotes technology transfer in the pharmaceutical industry. The non-profit company is based in Geneva, Switzerland. The Swiss company believes that technology transfer helps bridge research and development gaps, increases the availability of vaccines and medicines, and stimulates investment in key industrial areas. David Reddy has been the CEO of the company since 2024.

Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA.

Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium.

Sopartec SA is the investment and technology valorization arm of Université Catholique de Louvain (UCL) and was founded in 1942. Sopartec SA is headquartered in Louvain-la-Neuve, Belgium.

Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium.

Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands.

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands.

FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium.

Hunza Management SARL is a private equity firm headquartered in Luxembourg. The current firm was established in 1998 to manage Hunza Ventures, the venture capital investment vehicle of the family of the retired Belgian entrepreneur Guy Ullens. Baron Guy Ullens de Schooten and the Wittouck family built up and controlled the diversified European food manufacturing group Artal, based in Luxembourg and historically focused on the Belgian sugar industry.

Solvay Pharmaceuticals SA develops, manufactures, and supplies pharmaceutical products. The company's products include cardio-metabolics, influenza vaccines, adjuvants, and women's and men's healthcare products. It offers fenofibrate, a cardio-metabolic product for treating raised blood lipids and dyslipidemia products that control cholesterol and triglycerides. The firm is headquartered in Brussels, France.

reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium.

Exact Imaging, Inc. provides high resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its ExactVu micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. The company was founded by Sam Ifergan and Randy AuCoin in 2013 and is headquartered in Markham, Canada.

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands.

FEops NV develops novel simulation technology. It provides cardiovascular device and procedure simulation advice to medical device companies, as well as to medical specialists and physicians. The firm develops disruptive technology: a cloud-based simulation platform designed to assist clinicians in assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions. The company was founded by Benedict Verhegghe, Matthieu De Beule and Peter Mortier in 2009 and is headquartered in Ghent, Belgium.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA.

ViroVet NV is a Belgian company that focuses on the discovery, licensing, and development of biopharmaceutical products for livestock. The company is based in Leuven, Belgium. ViroVet was founded by Erwin Blomsma, Stefaan Wera, and Nesya Goris, with Erwin Blomsma serving as the CEO since incorporation.

Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands.

Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.

Aphea.Bio SA engages in research and development of biotechnology and agricultural products. It develops next generation biopesticides and biostimulants based on natural microorganisms. The company was founded by Isabel Vercauteren and Steven Vandenabeele in December 5, 2016 and is headquartered in Ghent, Belgium.

Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium.

Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium.

EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.

Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation.

Pulsify Medical BV is a Belgian digital medical technology company that specializes in developing wearable ultrasound patches. The company is based in Louvain, Belgium. Pulsify Medical was founded in 2019 by Lieven Herbots, Xavier Rottenberg, Jan D'hooge, Steve Stoffels. Iwan van Vijfeijken has been the CEO of the company since 2019.

Field Trip Health, Inc. operates as mental wellness firm. It offers ketamine-enhanced psychotherapy and psychedelic medicine services. The company was founded by Ronan Levy, Joseph del Moral, Hannan Fleiman, Mujeeb Jafferi, and Ryan Yermus on November 1, 2019 and is headquartered in Toronto, Canada.

Field Trip Psychedelics, Inc. operates as a mental wellness company. It offers psychedelics and psychedelic-enhanced therapies. The company was founded on April 2, 2019 and is headquartered in Toronto, Canada.

Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen.

Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands.

TigaTx BV is a Dutch company that provides research and development in the field of health nutrition. The company is based in Utrecht, the Netherlands. The company was founded in 2020 by Jeanette Leusen.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.

TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer.